के केन्द्रीय निर्गम मूल्यों में पिछला संशोधन 28-12-1991 से हुआ था । चूंकि 1992 के दौरान केन्द्रीय सरकार ने गेहूं और धान के वसूली मूल्यों में संशोधन करके वृद्धि कर दी है, अत: खाद्यान्नों पर राजसहायता के भार में 1991-92 में दी गई राजसहायता के स्तर से कमी होने की संभावना नहीं है ।

तथापि, केन्द्रीय सरकार ने देश में खाद्य की चिरकालिक कमी वाले क्षेत्रों में रहने वाले लोगों के लिए अधिक मात्रा उपलब्ध कराने तथा उनकी क्रय क्षमता बढ़ाने की दृष्टि से संपुष्ट सार्वजनिक वितरण प्रणाली की योजना के अंतर्गत अभिज्ञात खण्डों में वितरण के प्रयोजनार्थ चावल और गेहूं के केन्द्रीय निर्गम मूल्यों में सामान्य सार्वजनिक वितरण प्रणाली के केन्द्रीय निर्गम मूल्यों की तुलना में 50/- रु. प्रति क्विंटल की कमी की है ।

Amount due under DPEA

*48. SHRI H. HANUMANTHAPPA :

SHRIMATI SATYA BAHIN :

Will the PRIME MINISTER be pleased to State :

(a) What is the progress of recoveries made from the drug companies under DPEA during the last two years, upto 30th October 1992.

(b) what are the details of amounts recovered from each company during this period;

(c) what are the names of the companies in whose case assessment is still to be made;

(d) what are the names of companies to whom notices were sent but details have not been received till today; and

(e) whether Government have taken any action against these companies under the Essential Commodities Act; if so, the details thereof;

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN) :

(a) to (b) The government is making all possible efforts to make recovery under the DPEA including contesting various court cases filed by drug companies and sending notices to recover the amount as arrears of land revenue. There has been no recovery into the DPEA from the drug companies during the last two years upto 30th October, 1992. However in one case the company has recently deposited Rs. 37.34 lacs in the Bombay High Court as per the directions of the Supreme Court.

(c) to (e) A Statement giving the names of the companies against whom recoverable amounts are yet to be assessed is attached. (*See* below) : The process of assessment entails scrutiny of relevant data regarding production, sales and sale prices. The delay has occurred on account of non-receipt of requisite data from the companies in a number of cases. All efforts are being made to finalise the assessment as quickly as possible. In a number of cases the companies have already been informed that if they do not provide the data to the Government for computing their liability, the Government will be left with no alternative but to compute the liability on the basis of whatever data becomes available from wherever. Action against these companies would be taken after finalising liabilities against them.

Statement

DPEA CLAIMS—LIST OF COMPANIES TO WHOM LETTERS WERE ISSUED AND AGAINST WHOM RECOVERABLE AMOUNTS ARE TO BE ASSESSED.

1. M/s Abbott
2. M/s Albert David
3. M/s Alembic Chemicals
4. M/s Alta Labs
5. M/s Ambalal Sarabhai
6. M/s American Products
7. M/s Anglo French
8. M/s Ariste Pharma

9. M/s Astra IDL Ltd.
10. M/s BCPL
11. M/s Bayer (I) Ltd.
12. M/s Bengal Chemicals
13. M/s Bengal Immunity
14. M/s Biddle Sawyer
15. M/s Biochem Pharma
16. M/s Biological Evans
17. M/s Boehringer Knoll
18. M/s Bombay Drug House
19. M/s Bombay Tablets
20. M/s Boots
21. M/s Burroughs Wellcome
22. M/s Cadila Chemicals
23. M/s Cadila Labs.
24. M/s Cadila Pharma
25. M/s Chemo Pharma
26. M/s Cipla
27. M/s Concept Pharma
28. M/s Cyanamid
29. M/s DCI Pharma
30. M/s Dexo Labs
31. M/s Deys Medical Stores
32. M/s Dolphin Labs
33. M/s DWD Pharma
34. M/s East India Pharma
35. M/s Eros Pharma
36. M/s Eskayef
37. M/s FDC P. Ltd.
38. M/s Franco Indian Pharmaceuticals
39. M/s Fulford
40. M/s Geoffrey Manners
41. M/s German Remedies
42. M/s Glindia Ltd.
43. M/s Gufic (P) Ltd.
44. M/s HAL
45. M/s Hoechst
46. M/s IDPL
47. M/s IPCA
48. M/s Ifunik Pharma
49. M/s Indo German Alkaloids Ltd.
50. M/s Indo Pharma
51. M/s Indoco Remedies
52. M/s Inga Labs., Bombay
53. M/s Jagson Pal Pharma, New Delhi
54. M/s John Wyeth
55. M/s Kerala State Drugs & Pharmaceuticals
56. M/s Khandelwal Labs
57. M/s Lupin Labs
58. M/s Lyka Labs
59. M/s Mac Labs
60. M/s Maharashtra Antibiotics
61. M/s Martin & Harris Ltd.
62. M/s May & Baker
63. M/s Mercury Labs
64. M/s Merind
65. M/s Neo Pharma
66. M/s Nicholas Labs
67. M/s Okasa
68. M/s PCI Bombay
69. M/s Panama Industries
70. M/s Parke Davis
71. M/s Pfizer
72. M/s Pharmaceutical & Chemical Industries
73. M/s Pharmaceutical Co. of India Ltd.
74. M/s Pharmed (P) Ltd.
75. M/s Rallis India
76. M/s Ranbaxy Ltd.
77. M/s Roche Products
78. M/s Roussel Pharma
79. M/s S. G. Pharma
80. M/s SSPL
81. M/s Sandoz (I) Ltd.
82. M/s Sarabhai Chemicals
83. M/s Sarvodaya Labs
84. M/s Searle
85 M/s South India Research Inst.
86. M/s Stadmed
87. M/s Standard Pharma
88. M/s Suneeta Labs
89. M/s Synip Thio-Kof
90. M/s Synthico Formulations
91. M/s Syntho Pharma, Lucknow
92. M/s Tablets Ltd.
93. M/s Tamilnadu Dadha
94. M/s Themis Chemicals
95. M/s Themis Pharma
96. M/s Therapeutic Pharma
97. M/s U. S. Vitamins
98. M/s Unichem Labs
99. M/s Unique Pharma
100. M/s Universal Generics
101. M/s Walter Bushnell, Bombay

102. M/s Warner Hindustan
103 M/s Wockhardt
104. M/s Wyeth Labs
105. M/s Yash Pharma
106. M/s Zandu Pharma

Overcharging for Bulk Drugs by Pharmaceutical Units

*49. SMT. SARALA MAHESHWARI : SHRI MD. SALIM :

Will the PRIME MINISTER be pleased to state :

(a) whether it is a fact that some units in the pharmaceutical industry are charging higher prices for bulk drugs than those notified by Government;

(b) if so, whether these units have been identified; and

(c) whether any punitive action has been initiated against any of these units ?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZER (SHRI CHINTA MOHAN) : (a) to (c) This Department received some complaints alleging overcharging of prices of certain bulk drugs. The names of these bulk drugs are given in the annexed Statement. (*See* below). As and when any complaint of alleged over charging of bulk drugs and formulations is received, the same is forwarded to the concerned State Drug Control Administration for investigation and necessary action under the Essential Commodities Act, 1955. The companies concerned are also asked to explain the position. To the extent information is available State Drug Controller, Maharashtra has filed complaints in Court of Law against 9 parties including traders and manufacturers. State Drug Controllers of other States have not so far reported any instance where punitive action has been initiated.

Statement

Sr. No.	Name of the Bulk Drug
1.	Vitamin C Plain
2.	Vitamin C Coated
3.	Sodium Ascorbate
4.	Prednisolone
5.	Rifampicin
6.	Erythromycin Stearate
7.	Ampicilin Trihydrate
8.	Trimethoprim
9.	Metronidazole
10.	Metronidazole Benzoate
11.	Pyrazinamide
12.	Di Ethyl Carbamazine Citrate
13.	Ethambutol Hcl
14.	Cloxacullin Sodium (Oral Grade)
15.	Chloroquine Phosphate
16.	Sulphamethoxazole
17.	Tetracycline Hcl
18.	Analgin
19.	Amoxycillin Trihydrate
20.	Cephalexin

संयुक्त राष्ट्र संघ के पुनर्गठन के संबंध में गुटनिरपेक्ष शिखर सम्मेलन में विचार-विमर्श

*50. श्री अनन्तराम जायसवाल : क्या प्रधान मंत्री यह बताने की कृपा करेंगे कि :

(क) क्या यह सच है कि सितम्बर, 1992 के प्रथम सप्ताह में जकार्ता में सम्पन्न हुए गुटनिरपेक्ष शिखर सम्मेलन में संयुक्त राष्ट्र संघ के पुनर्गठन पर विचार किया गया था;

(ख) यदि हां, तो शिखर सम्मेलन में हुए विचार-विमर्श का क्या परिणाम निकला है; और

(ग) क्या सरकार का इस संबंध में पहल करने का इरादा है ?

विदेश मंत्रालय में राज्य मंत्री (श्री एच. आर्डो फेलेरियो) : (क) जी, हां ।